A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.
Participation in the study will last about 80 weeks.
Inclusion Criteria:
Are on stable incretin therapy at screening
With persistent obesity or overweight defined as:
≥30 kg/m2 OR
≥27 kg/m2 with at least one existing obesity related complication at screening:
Have a stable body weight (<5% body weight change) at screening
Exclusion Criteria:
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes
Have taken any of the following antihyperglycemic medications within 90 days before screening:
Have had within 90 days prior to screening:
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
LillyTrials@Lilly.com317-615-4559
clinical_inquiry_hub@lilly.com
Birmingham, Alabama 35209, United States
205-870-4343
Tucson, Arizona 85741, United States
Troy, Michigan 48098, United States
Chapel Hill, North Carolina 27514, United States
Wilmington, North Carolina 28401, United States
Pittsburgh, Pennsylvania 15236, United States
Luoyang Shi, 471023, China
13653880139
Nanjing, 210011, China
Wenzhou, 315100, China
Guadalajara, 44670, Mexico
Kaohsiung Niao Sung Dist, 83301, Taiwan
+886912159389
480-966-7882
480-725-8708
949-753-1663
858-824-5352
619-460-2626
310-265-1623
925-734-2331
858-278-3647
714-474-2173
714-734-7944
203-374-9816
203-785-7421
203-419-4420
561-968-2933
904-541-8225
904-730-0101
305-226-3933
904-209-0043
561-802-3060
470-403-4755
770-534-5154
770-507-6867
208-552-7700
773-275-3500 Ext 162
785-354-9591
859-264-8999
410-730-3399
617-732-4245
617-744-1310
248-864-5242
248-829-3103
248-312-0025
636-220-1200
212-263-3166
646-962-2111
984-974-3004
336-763-6968
252-499-8623
910-799-5500
513-721-3868
412-650-6155
843-994-7655
713-779-5494
832-969-3401
832-532-4210
210-692-7157
518-428-6859
210-545-4900
956-431-8090
469-449-3645
+61736468111
0394962160
+61 2 4963 2323
0874258693
003215505164
3289807250
+3257357270
003256633180
3216346994
+3215892042
003215792797
059414160
5541999736442
554130231252
55 85 3214.6530
551126303777
551131479432
55 27 99933-3330
55017997472217
15843081103
18980601658
13594028475
86-13956099720
13767035719
18951670116
18951762960
13757426626
13651913857
13806542929
18391081568
420573399559
420272917011
420257211886
97246495139
04-9842020
972-8-6403896
04-7744931
972-4-7771606
972-35028392
97226776927
972-97472559
+97248781555
+97298362745
972-3-9372429
+97239377183
97235302021
9729441895
97246745729
97236900333
97236973415
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
81120023812
523336165410 400
52 55 9185 9959
686 5534121
52 8141916867
528113578379
7872696590
7874045252
40721203324
0040762249010
40314288633
0040212323445
0040241740581
004 0722 480 224
40746013882
0040724372432
0040745641194
0723377127
655624017
0034678510067
34697817352
34 871 205256
34914522000
34639659866
+ 34 954709183
670502836
658011529
886-5-2765041
886-7-3121101 ext 7741
886923832500
886 62353535 ext 3985
0223123456
886-2-2737-2181 ext 8481
886228757516